Concurrent radiotherapy, paclitaxel and dose escalating carboplatin in the treatment of cervical cancer--a phase I study.
BACKGROUND
Concurrent radiation therapy (RT) and chemotherapy represents the standard treatment of locally advanced cervical cancer. This study was designed to determine the feasibility and toxicity of concomitant administration of RT with twice per week paclitaxel and carboplatin.


METHODS
Nine women with cervical cancer stage IB2-IVA were treated with standard RT and twice per week paclitaxel at a dose of 30 mg/m2 with carboplatin in escalating doses starting at an AUC of 5.


RESULTS
One out of the four patients who received carboplatin at AUC 5 developed grade III toxicity according to the National Cancer Institute (NCI) grading system. Two out of the five patients who received carboplatin at AUC 6 developed grade III toxicity. A clinical response was achieved in 8 patients (89%), with a complete response (CR) in 5 patients (56%).


CONCLUSIONS
Combining RT with twice weekly paclitaxel (30 mg/m2) and carboplatin (AUC of 6) is a tolerated regimen, active in controlling locally advanced cervical cancer.
Addeo
Daniela
D
New York University, Department of Radiation Oncology, New York, NY 10016, USA. DGide@aol.com
Blank
Stephanie
S
Muggia
Franco
F
Formenti
Silvia
S
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D055815:Young Adult
D016190:Carboplatin; D017239:Paclitaxel